Devyser Diagnostics AB (FRA:OL0) Research & Development: €1.49 Mil (TTM As of Mar. 2026)


FRA:OL0 Devyser Diagnostics AB FRA:OL0
77 GF Score
Price €7.59
GF Value €14.06
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Devyser Diagnostics AB Research & Development?

Devyser Diagnostics AB FRA:OL0 77 Research & Development is €1.49 Mil as of Mar. 2026. GuruFocus rates FRA:OL0 with a GF Score™ of 77/100 and a GF Value™ of €14.06 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Devyser Diagnostics AB's Research & Development for the three months ended in Mar. 2026 was €0.50 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €1.49 Mil.

Devyser Diagnostics AB  (FRA:OL0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Devyser Diagnostics AB Research & Development Related Terms

Devyser Diagnostics AB Research & Development Historical Data

* Premium members only.

The historical data trend for Devyser Diagnostics AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devyser Diagnostics AB Research & Development Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 1.76 2.39 3.38 3.75 1.65

Devyser Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.45 0.32 0.22 0.50
FRA:OL0
77GF Score
Devyser Diagnostics AB FRA:OL0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devyser Diagnostics AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €1.49 Mil mean?
Devyser Diagnostics AB (FRA:OL0) has a Research & Development of €1.49 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Devyser Diagnostics AB and its competitors.
Is Devyser Diagnostics AB's Research & Development too high?
Devyser Diagnostics AB's current Research & Development is €1.49 Mil. Overall, Devyser Diagnostics AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's Research & Development compare to ABT and SYK?
Devyser Diagnostics AB's Research & Development of €1.49 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Devyser Diagnostics AB and its competitors. Devyser Diagnostics AB's current Research & Development is €1.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Devyser Diagnostics AB (FRA:OL0) is currently considered Significantly Undervalued. The stock's GF Value™ is €14.06, compared to a current price of €7.59 — trading 46% below its estimated fair value. The current Research & Development is €1.49 Mil. Devyser Diagnostics AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current Research & Development is €1.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?

Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued. The current stock price of €7.59 is trading 46% below its estimated GF Value™ of €14.06. GuruFocus considers Devyser Diagnostics AB to be Significantly Undervalued.

Key valuation signals for FRA:OL0:

  • Research & Development: €1.49 Mil
  • GF Value™: €14.06 vs. price of €7.59 (46% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devyser Diagnostics AB Business Description

Other Exchanges DVYSR:Sweden
Address Branningevagen 12, Arsta, SWE, 120 54
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
77GF Score

Get the complete analysis for FRA:OL0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.59
Price
€14.06
GF Value